CAJ | 학술논문

目的：观察异甘草酸镁在肝动脉栓塞化疗（ TACE）中的保肝作用。方法：将72例原发性肝癌患者随机分为对照组与治疗组。对照组仅给予肝动脉栓塞化疗和营养支持治疗，治疗组在对照组治疗基础上加用异甘草酸镁（150mg/d）行保肝治疗，连续用药14d。结果：2组治疗后临床症状均明显改善（P＞0．05），但在复常天数上有明显差异（P＜0．05）。治疗组治疗前、后肝功能指标水平无变化，TACE结束后第3天、7天对照组总胆红素均显著高于治疗组（ P ＜0．01），TACE结束后第14天有所下降，但仍高于治疗组（ P ＜0．05）；TACE结束后第3天、7天对照组丙氨酸氨基转移酶和天门冬酸氨基转移酶较治疗组明升高（ P ＜0．01）， TACE结束后第14天降至正常；对照组白蛋白与治疗组比较：TACE结束后第7天开始明显下降（ P ＜0．05）， TA-CE结束后第14天有所回升，但未至正常水平（ P ＜0．05）。结论：异甘草酸镁可以防止正常肝细胞损害，保护肝功能，增强患者对栓塞化疗的耐受性。
목적：관찰이감초산미재간동맥전새화료（ TACE）중적보간작용。방법：장72례원발성간암환자수궤분위대조조여치료조。대조조부급여간동맥전새화료화영양지지치료，치료조재대조조치료기출상가용이감초산미（150mg/d）행보간치료，련속용약14d。결과：2조치료후림상증상균명현개선（P＞0．05），단재복상천수상유명현차이（P＜0．05）。치료조치료전、후간공능지표수평무변화，TACE결속후제3천、7천대조조총담홍소균현저고우치료조（ P ＜0．01），TACE결속후제14천유소하강，단잉고우치료조（ P ＜0．05）；TACE결속후제3천、7천대조조병안산안기전이매화천문동산안기전이매교치료조명승고（ P ＜0．01）， TACE결속후제14천강지정상；대조조백단백여치료조비교：TACE결속후제7천개시명현하강（ P ＜0．05）， TA-CE결속후제14천유소회승，단미지정상수평（ P ＜0．05）。결론：이감초산미가이방지정상간세포손해，보호간공능，증강환자대전새화료적내수성。
Objective:To observe the hepatoprotective effect of Magnesium Isoglycyrrhizinate Injection on patients undergoing tran -scatheter arterial chemoembolization ( TACE) .Methods:A total of 46 patients with primary hepatocellular carcinoma ( PHC) were random-ized to trial and control group .The control group received supporting treatment alone from the first TACE day ,while the trial group received Magnesium Isoglycyrrhizinate Injection 150 mg/d in combination with supporting treatment for 10 consecutive days .Results:The symptoms of two groups were significantly improved (P >0.05),but the improving days had significant differences (P<0.05).The trial group showed no significant differences in parameters of liver function before and after receiving TACE On days 3 and 7 after the completion of TACE,the total bilirubin level in control group was significantly higher than in trial group ( P <0.01),but slightly reduced on days 14, yet it was still higher than in the trial group ( P <0.05) On days 3 and 7 after the completion of TACE ,the ALT and AST levels in the control group ( P <0.01) were significantly higher than in the trial group ( P <0.01) , but reduced to the normal level on days 14;the ALB level began to decrease significantly from day 7 after the completion of TACE ( P <0.05),but rebounded slightly on day 14 , yet it failed to return to the normal level ( P <0.05) .Conclusion:Magnesium Isoglycyrrhizinate Injection could prevent hepatocellular damage and protect liver function and enhance patients'tolerance to TACE.